tbuckley/cabot-search huggingface dataset:
Proposing <i>GLMN</i>, encoding glomulin, as a novel gene for Dowling-Degos disease
Authors: Sheetal Kumar, Regina C Betz, Jorge Frank
Journal: British Journal of Dermatology (2024)

Dowling-Degos disease (DDD) is a rare hyperpigmentation disorder with autosomal-dominant inheritance. To date, work by our group and others has identified a total of four DDD sub-phenotypes, which arise secondary to variants in KRT5, POFUT1, POGLUT1, and PSENEN. We postulate that GLMN is a novel fifth gene for DDD that contributes to a hitherto unrecognized DDD sub-phenotype.
Patients with Delusional Infestation are being given conflicting advice by pharmacy colleagues
Authors: Pirunthan Pathmarajah, Maria-Angeliki Gkini, Ruth E Taylor, Anthony Bewley
Journal: British Journal of Dermatology (2024)

The role of pharmacists in psychodermatology includes counseling patients on psychotropic medications, ensuring adherence, and providing guidance that complements the advice of dermatology health care professionals. This pilot study is the first to highlight discrepancies in counselling effectiveness between clinicians and pharmacists. Patients were provided with suboptimal, conflicting or contradictory advice and training specialized pharmacists with prescribing privileges and providing specific information on psychotropic medications are essential.
Interventions to reduce low-value care in intensive care settings: a scoping review of impacts on health, resource use, costs, and the environment
Authors: Jake T. W. Williams, Florencia Moraga Masson, Forbes McGain, Rachel Stancliffe, Julia K. Pilowsky, Nhi Nguyen, Katy J. L. Bell
Journal: Intensive Care Medicine (2024)

Low-value care is common in intensive care units (ICUs), unnecessarily exposing patients to risks and harms, incuring costs to the patient and healthcare system, and contributing to healthcare's carbon footprint. We aimed to identify, collate, and summarise published evidence on the impact of interventions to reduce low-value care in ICUs.
Cardiomyopathy: pathogenesis and therapeutic interventions
Authors: Shitong Huang, Jiaxin Li, Qiuying Li, Qiuyu Wang, Xianwu Zhou, Jimei Chen, Xuanhui Chen, Abdelouahab Bellou, Jian Zhuang, Liming Lei
Journal: MedComm (2024)

Abstract Cardiomyopathy is a group of disease characterized by structural and functional damage to the myocardium. The etiologies of cardiomyopathies are diverse, spanning from genetic mutations impacting fundamental myocardial functions to systemic disorders that result in widespread cardiac damage. Many specific gene mutations cause primary cardiomyopathy. Environmental factors and metabolic disorders may also lead to the occurrence of cardiomyopathy. This review provides an in‐depth analysis of the current understanding of the pathogenesis of various cardiomyopathies, highlighting the molecular and cellular mechanisms that contribute to their development and progression. The current therapeutic interventions for cardiomyopathies range from pharmacological interventions to mechanical support and heart transplantation. Gene therapy and cell therapy, propelled by ongoing advancements in overarching strategies and methodologies, has also emerged as a pivotal clinical intervention for a variety of diseases. The increasing number of causal gene of cardiomyopathies have been identified in recent studies. Therefore, gene therapy targeting causal genes holds promise in offering therapeutic advantages to individuals diagnosed with cardiomyopathies. Acting as a more precise approach to gene therapy, they are gradually emerging as a substitute for traditional gene therapy. This article reviews pathogenesis and therapeutic interventions for different cardiomyopathies.
Metabolic regulation of intestinal homeostasis: molecular and cellular mechanisms and diseases
Authors: Ruolan Zhang, Ansu Perekatt, Lei Chen
Journal: MedComm (2024)

Abstract Metabolism serves not only as the organism's energy source but also yields metabolites crucial for maintaining tissue homeostasis and overall health. Intestinal stem cells (ISCs) maintain intestinal homeostasis through continuous self‐renewal and differentiation divisions. The intricate relationship between metabolic pathways and intestinal homeostasis underscores their crucial interplay. Metabolic pathways have been shown to directly regulate ISC self‐renewal and influence ISC fate decisions under homeostatic conditions, but the cellular and molecular mechanisms remain incompletely understood. Understanding the intricate involvement of various pathways in maintaining intestinal homeostasis holds promise for devising innovative strategies to address intestinal diseases. Here, we provide a comprehensive review of recent advances in the regulation of intestinal homeostasis. We describe the regulation of intestinal homeostasis from multiple perspectives, including the regulation of intestinal epithelial cells, the regulation of the tissue microenvironment, and the key role of nutrient metabolism. We highlight the regulation of intestinal homeostasis and ISC by nutrient metabolism. This review provides a multifaceted perspective on how intestinal homeostasis is regulated and provides ideas for intestinal diseases and repair of intestinal damage.
Platelet Extracellular Vesicles Loaded Gelatine Hydrogels for Wound Care
Authors: Florence Back, Alexandre Barras, Ariunjargal Nyam‐Erdene, Jen‐Chang Yang, Sorin Melinte, José Rumipamba, Thierry Burnouf, Rabah Boukherroub, Sabine Szunerits, Er‐Yuan Chuang
Journal: Advanced Healthcare Materials (2024)

Abstract Platelet extracellular vesicles (pEVs) isolated from clinical‐grade human platelet concentrates are attracting attention as a promising agent for wound healing therapies. Although pEVs have shown potential for skin regeneration, their incorporation into wound bandages has remained limitedly explored. Herein, gelatine‐based hydrogel (PAH‐G) foams for pEVs loading and release are formulated by crosslinking gelatine with poly(allylamine) hydrochloride (PAH) in the presence of glutaraldehyde and sodium bicarbonate. The optimized PAH‐G hydrogel foam, PAH 0.24 G 37 , displayed an elastic modulus G’ = 8.5 kPa at 37 °C and retained a rubbery state at elevated temperatures. The excellent swelling properties of PAH 0.24 G 37 allowed to easily absorb pEVs at high concentration (1 × 10 11 particles mL −1 ). The therapeutic effect of pEVs was evaluated in vivo on a chronic wound rat model. These studies demonstrated full wound closure after 14 days upon treatment with PAH 0.24 G 37 @pEVs. The maintenance of a reduced‐inflammatory environment from the onset of treatment promoted a quicker transition to skin remodeling. Promotion of follicle activation and angiogenesis as well as M1–M2 macrophage modulation are evidenced. Altogether, the multifunctional properties of PAH 0.24 G 37 @pEVs addressed the complex challenges associated with chronic diabetic wounds, representing a significant advance toward personalized treatment regimens for these conditions.
Partial reduction of interleukin‐33 signaling improves senescence and renal injury in diabetic nephropathy
Authors: Li Chen, Chao Gao, Xingzhu Yin, Li Mo, Xueer Cheng, Huimin Chen, Chunjie Jiang, Bangfu Wu, Ying Zhao, Hongxia Li, Yanyan Li, Jiansha Li, Liangkai Chen, Qianchun Deng, Ping Yao, Yuhan Tang
Journal: MedComm (2024)

Abstract Diabetic nephropathy (DN) is a frequent and costly complication of diabetes with limited understandings of mechanisms and therapies. Emerging evidence points to the important roles of interleukin‐33 (IL‐33) in acute kidney injury, yet its contribution to DN is still unclear. We here found a ubiquitous increase of IL‐33 and its receptor (ST2) in murine models and patients with DN. Surprisingly, both IL‐33 and ST2 knockdown aggravated renal lesions in DN, while overexpression of IL‐33 also exacerbated the condition. Further population‐based analyses revealed a positive correlation of IL‐33 expression with renal dysfunction in DN patients. Individuals with high IL‐33 expression‐related polygenic risk score had a higher DN risk. These findings confirmed the harmful effects of IL‐33 on DN. Conversely, endogenous and exogenous partial reduction of IL‐33 signaling conferred renoprotective effects in vivo and in vitro. Mechanistically, IL‐33 induced senescence by regulating cell cycle factors in HK‐2 cells, and accordingly senescence led to renal cell damage through the secretion of senescence‐related secretory phenotype (SASP) including IL‐33 and prostaglandins. Together, elevated IL‐33 accelerates cellular senescence to drive DN possibly by SASP production, while a partial blockage improves renal injury and senescence. Our findings pinpoint a possible and new avenue for DN interventions.
Point‐of‐care breath sample analysis by semiconductor‐based E‐Nose technology discriminates non‐infected subjects from SARS‐CoV‐2 pneumonia patients: a multi‐analyst experiment
Authors: Tobias Woehrle, Florian Pfeiffer, Maximilian M. Mandl, Wolfgang Sobtzick, Jörg Heitzer, Alisa Krstova, Luzie Kamm, Matthias Feuerecker, Dominique Moser, Matthias Klein, Benedikt Aulinger, Michael Dolch, Anne‐Laure Boulesteix, Daniel Lanz, Alexander Choukér
Journal: MedComm (2024)

Metal oxide sensor-based electronic nose (E-Nose) technology provides an easy to use method for breath analysis by detection of volatile organic compound (VOC)-induced changes of electrical conductivity. Resulting signal patterns are then analyzed by machine learning (ML) algorithms. This study aimed to establish breath analysis by E-Nose technology as a diagnostic tool for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pneumonia within a multi-analyst experiment. Breath samples of 126 subjects with (
Clinical characteristics and prognosis of bloodstream infections with carbapenem-resistant Gram-negative organisms in patients with hematological malignancies: a multicenter case-control study in China
Authors: Junxin Zhou, Jian Sun, Shanshan Lu, Xinhong Han, Jintao He, Ping Zhang, Huangdu Hu, Yuke Zhang, Yanfei Wang, Qin Yang, Shujuan Ji, Zhihui Zhou, Xiaoting Hua, Xueqing Wu, Yan Jiang, Xiaoxing Du, Yunsong Yu
Journal: Journal of Infection (2024)
Anti-integrin αvβ6 autoantibodies are increased in PSC patients with concomitant IBD and correlate with liver disease severity
Authors: Hannah Bloemen, Alexandra E Livanos, Adrielly Martins, Richard Dean, Ana Catarina Bravo, Arno R Bourgonje, Michael Tankelevich, Jake Herb, Judy Cho, André Anastácio Santos, Cecília M P Rodrigues, Francesca Petralia, Jean-Frederic Colombel, Christopher L Bowlus, Thomas Schiano, Joana Torres, Cynthia Levy, Saurabh Mehandru
Journal: Clinical Gastroenterology and Hepatology (2024)
Robust tetra‐armed poly (ethylene glycol)‐based hydrogel as tissue bioadhesive for the efficient repair of meniscus tears
Authors: Jing Ye, Yourong Chen, Ronghui Deng, Jiying Zhang, Hufei Wang, Shitang Song, Xinjie Wang, Bingbing Xu, Xing Wang, Jia‐Kuo Yu
Journal: MedComm (2024)

Repair and preservation of the injured meniscus has become paramount in clinical practice. However, the complexities of various clinic stitching techniques for meniscus repair pose challenges for grassroots doctors. Hence, there is a compelling interest in innovative therapeutic strategies such as bioadhesives. An ideal bioadhesive must cure quickly in aqueous and blood environments, bind strongly, endure arthroscopic washing pressures, and degrade appropriately for tissue regeneration. Here, we present a tetra-poly (ethylene glycol) (PEG)-based hydrogel bioadhesive, boasting high biocompatibility, ultrafast gelation, facile injectable operation, and favorable mechanical strength. In view of the synergistic effects of chemical anchor and physical chain entanglement to tightly bind the meniscus, a seamless interface was formed between the surrounding meniscal tissues and hydrogels, enabling the longitudinal tear of the meniscus fused in situ to withstand large tensile force with the adhesive strength of 541.5 ± 31.4 kPa and arthroscopic washout resistance of 29.4 kPa. Superior to existing commercial adhesives, ours allows sutureless application and arthroscopic assistance, without requiring specialized clinical skills. This research is expected to significantly impact our understanding of meniscal healing and ultimately promote a simpler process for achieving functional and structural recovery in torn menisci.
SPI1<sup>+</sup>CD68<sup>+</sup>macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies
Authors: Guofei Deng, Pengliang Wang, Rishun Su, Xuezeng Sun, Zizhen Wu, Zhangsen Huang, Liang Gu, Hong Yu, Zhenzhen Zhao, Yulong He, Mingyu Huo, Changhua Zhang, Songcheng Yin
Journal: Journal for ImmunoTherapy of Cancer (2024)

Tumor-associated macrophages (TAMs) have been demonstrated to be associated with tumor progression. However, the different subpopulations of TAMs and their roles in gastric cancer (GC) remain poorly understood. This study aims to assess the effects of Spi-1 proto-oncogene (SPI1)
Biofilm Microenvironment‐Sensitive Anti‐Virulent and Immunomodulatory Nano‐on‐Nanodroplets to Combat Refractory Biofilm Infection Through Toxin Neutralization and Phagocytosis
Authors: Somashree Bose, Sujoy K Das
Journal: Advanced Healthcare Materials (2024)

Abstract Biofilm‐associated wound infection is principally perceived as the bacterial defense mechanism that hinders antibiotic penetration, causes toxin impairment, and suppresses the immunological responses of the host immune system. Several antibiofilm agents have been developed, but the least of these agents can simultaneously cornerstone on the biofilm‐associated immunosuppression and bacterial toxin‐induced cellular dysfunction. Inspired by the fusogenic property of nanodroplets and immunomodulatory functions of metal nanoparticles, biofilm targeted anti‐virulent immunomodulatory cationic nanoparticle shelled nanodroplets (C‐AgND) is fabricated to completely disintegrate and eradicate the Staphylococcus aureus (S. aureus) biofilm. The specific binding of C‐AgND neutralizes the negatively charged EPS layer, causing their destabilization followed by penetration of the nanoformulation into the biofilm matrix, killing the persister cells. Consequently, C‐AgND eliminates the virulence property of the S. aureus biofilm through α‐hemolysin neutralization. C‐AgND promotes a strong immunomodulatory effect by polarizing macrophages into their M1 phenotype to induce phagocytosis of the disintegrated biofilm‐released residual cells, rejuvenating the host's innate immune responses for the complete eradication of the biofilm. Moreover, the ex vivo skin wound infection model illustrates an excellent biofilm eradication efficacy of C‐AgND in comparison to the commercial ones, rendering them to be a promising replacement of existing antibiofilm agents in clinical application.
Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma
Authors: Lianmin Zhang, Yanan Cui, Guangyao Zhou, Zhenfa Zhang, Pengpeng Zhang
Journal: Journal for ImmunoTherapy of Cancer (2024)

Lung adenocarcinoma (LUAD) is a highly heterogeneous disease, posing significant challenges to accurate prognosis prediction. Mitochondria play a central role in the energy metabolism of eukaryotic cells and can influence programmed cell death (PCD) mechanisms, which are critical in tumorigenesis and cancer progression. However, the prognostic significance of the interplay between mitochondrial function and PCD in LUAD requires further investigation.
Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway
Authors: Hua Huang, Yuwen Pan, Qiuwen Mai, Chunyu Zhang, Qiqiao Du, Yuandong Liao, Shuhang Qin, Yili Chen, Jiaming Huang, Jie Li, Tianyu Liu, Qiaojian Zou, Yijia Zhou, Li Yuan, Wei Wang, Yanchun Liang, Chao Yun Pan, Junxiu Liu, Shuzhong Yao
Journal: Journal for ImmunoTherapy of Cancer (2024)

Cervical cancer remains a global health challenge. The identification of new immunotherapeutic targets may provide a promising platform for advancing cervical cancer treatment.
Magneto‐Thermal Hydrogel Swarms for Targeted Lesion Sealing
Authors: Ziheng Chen, Hui Chen, Kaiwen Fang, Na Liu, Jiangfan Yu
Journal: Advanced Healthcare Materials (2024)

Abstract Magnetic microswarms capable of performing navigation to targeted lesions show great potential for in vivo medical applications. However, using the swarms for lesion cavity filling encounters challenges from precise delivery and sealing. Herein, this work develops a magneto‐thermal hydrogel swarm consisting of magnetic hydrogel particles, which can perform phase transition induced by temperature change. The particles are prepared using a temperature‐responsive hydrogel matrix, tissue adhesive monomers, and magnetic microparticles. The swarms can be remolded to various shapes, and it can be used to seal perforation in phantom and gastric tissue. The swarms can also serve as drug carriers, and their drug release profiles induced by temperature changes are characterized. Finally, the targeted delivery, adaptive filling, and sealing of a gastric ulcer using the swarms are achieved in ex vivo and in vivo environments.
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Authors: Zhiming Li, Wenqi Jiang, Hui Zhou, Hong Cen, Mingzhi Zhang, Fangfang Lv, Qingyuan Zhang, Xiuhua Sun, Lihong Liu, Yunhong Huang, Haiyan Yang, Sujun Gao, Chuan He, Wei Yang, Wenyu Li, Ding Yu, Yu Yang, Ying Cheng, Zhengzi Qian, Ying Xiang, Qunyi Guo, Bing Xu, Yuqin Song, Liling Zhang, Lie Lin, Jianzhen Shen, Feng Yan, Huilan Liu, Donghua Zhang, Jishi Wang, Min Zhou, Xiongpeng Zhu, Weihua Zhang, Weili Zhao, Ru Feng, Xiaohong Zhang, Jie Jin, Meizuo Zhong, Mei Zhang, Jingbo Wang, Hongmei Jing, Zhao Wang, Hongguo Zhao, Jun Zhu
Journal: Journal for ImmunoTherapy of Cancer (2024)

In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment regimens.
Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines
Authors: Yulu Teng, Zhenzhen Yang, Yiwei Peng, Yiliang Yang, Siyu Chen, Jiajia Li, Datong Gao, Wen Sun, Zinan Wu, Yanxia Zhou, Xinru Li, Xianrong Qi
Journal: Advanced Healthcare Materials (2024)

Abstract Dying tumor cells regulated by immunogenic cell death (ICD) inducers are promising candidates for cancer vaccine development because of their comprehensive antigen spectrum. However, their limited immunogenicity and potential tumorigenicity hinder clinical translation. To address these challenges, a nano‐orchestrator is developed that targets the endoplasmic reticulum (ER) stress, a critical pre‐ICD event, to optimize the “precise dose” of ER stress. Using a clinical‐range irradiation fluence (50‒200 J cm −2 ) with an 808 nm laser, the release of damage associated molecular patterns (DAMPs) and antigens are precisely regulated. A fluence of 150 J cm −2 (2 W cm −2 for 75 s) increases dendritic cell maturation and antitumor T cell proliferation, providing valuable clinical insights. The ER stress nano‐orchestrator enhances both adjuvanticity and antigenicity via the protein kinase R‐like endoplasmic reticulum kinase (PERK)‐C/EBP homologous protein (CHOP) pathway to regulate ICD‐induced DAMPs and promote tumor cell apoptosis. These optimized ER stress phototherapeutic dying tumor cells can serve as prophylactic vaccines, achieving a remarkable 100% success rate against tumor rechallenge in vivo. Additionally, the nano‐orchestrator shows the potential to develop in situ therapeutic tumor vaccines when combined with anti‐PD‐L1 treatment, providing important insights into enhancing the efficacy of immune checkpoint regulators by modulating endogenous immune responses.
Letter regarding the article ‘Predictors of the efficacy of His bundle pacing in patients with a prolonged <scp>PR</scp> interval: A stratified analysis of the <scp>HOPE</scp>‐<scp>HF</scp> randomized controlled trial’
Authors: Anja Zupan Mežnar, Miha Mrak, David Žižek
Journal: European Journal of Heart Failure (2024)
Surviving by a margin: Mohs outperforms wide local excision for lentigo maligna
Authors: Keegan O’Hern, Addison M Demer
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Surviving by a margin: Mohs outperforms wide local excision for lentigo maligna Get access Keegan O'Hern, Keegan O'Hern Department of Dermatology, Mayo Clinic, Rochester, MN, USA Corresponding author: Keegan O'Hern Email:ohern.keegan@mayo.edu Search for other works by this author on: Oxford Academic Google Scholar Addison M Demer Addison M Demer Division of Dermatologic Surgery, Mayo Clinic, Rochester, MN, USA Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae422, https://doi.org/10.1093/bjd/ljae422 Published: 25 October 2024 Article history Received: 12 October 2024 Accepted: 23 October 2024 Published: 25 October 2024
Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations
Authors: Marco Gallus, Jacob S Young, Sarah Cook Quackenbush, Mustafa Khasraw, John de Groot, Hideho Okada
Journal: Neuro-Oncology (2024)

Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in patients with malignant gliomas have shown some early promise in pediatric and adult patients. However, the long-term benefits and safety for patients remain to be established. The ultimate success of CAR T-cell therapy for malignant glioma will require the integration of an in-depth understanding of the immunology of the central nervous system (CNS) parenchyma with strategies to overcome the paucity and heterogeneous expression of glioma-specific antigens. We also need to address the cold (immunosuppressive) microenvironment, exhaustion of the CAR T-cells, as well as local and systemic immunosuppression. Here, we discuss the basics and scientific considerations for CAR T-cell therapies and highlight recent clinical trials. To help identify optimal CAR T-cell administration routes, we summarize our current understanding of CNS immunology and T-cell homing to the CNS. We also discuss challenges and opportunities related to clinical trial design and patient safety/monitoring. Finally, we provide our perspective on future prospects in CAR T-cell therapy for malignant gliomas by discussing combinations and novel engineering strategies to overcome immuno-regulatory mechanisms. We hope this review will serve as a basis for advancing the field in a multiple discipline-based and collaborative manner.